Analyst Price Targets — SGMO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 31, 2024 3:55 pm | Maury Raycroft | Jefferies | $3.00 | $1.02 | TheFly | Sangamo price target lowered to $3 from $7 at Jefferies |
| December 31, 2024 10:10 am | Yanan Zhu | Wells Fargo | $2.00 | $1.02 | TheFly | Sangamo price target lowered to $2 from $3 at Wells Fargo |
| June 13, 2022 7:25 am | Andreas Argyrides | Wedbush | $5.00 | $3.76 | TheFly | Sangamo assumed with a Neutral at Wedbush |
| April 5, 2022 12:00 am | Nicole Germino | Truist Financial | $19.00 | $6.15 | Pulse 2.0 | Sangamo BioSciences (SGMO) Stock: Why The Price Increased |
Latest News for SGMO
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo…
RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company's pipeline and financial resources, it has retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and to maximize value for…
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SGMO.
U.S. House Trading
No House trades found for SGMO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.